Difference between revisions of "Drug index"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.")
(25 intermediate revisions by the same user not shown)
Line 36: Line 36:
 
*[[Acalabrutinib (Calquence)]]
 
*[[Acalabrutinib (Calquence)]]
 
*[[Aclarubicin (Aclacinomycin)]]
 
*[[Aclarubicin (Aclacinomycin)]]
−
*[[Adagrasib (Krazati)]] '''FDA approved 2022-12-12'''
+
*[[Adagrasib (Krazati)]]
 
*[[Afatinib (Gilotrif)]]
 
*[[Afatinib (Gilotrif)]]
 
*[[Aldesleukin (Proleukin)]]
 
*[[Aldesleukin (Proleukin)]]
Line 81: Line 81:
 
*[[Benralizumab (Fasenra)]]
 
*[[Benralizumab (Fasenra)]]
 
*[[Bevacizumab (Avastin)]]
 
*[[Bevacizumab (Avastin)]]
−
**[[Bevacizumab-adcd (Vegzelga)]] '''FDA approved 2022-09-28'''
+
**[[Bevacizumab-adcd (Vegzelga)]]
 +
**[[Bevacizumab-aveg (Avegra)]]
 
**[[Bevacizumab-awwb (Mvasi)]]
 
**[[Bevacizumab-awwb (Mvasi)]]
 +
**[[Bevacizumab-aybi (Aybintio)]]
 
**[[Bevacizumab-bvzr (Zirabev)]]
 
**[[Bevacizumab-bvzr (Zirabev)]]
 +
**[[Bevacizumab-equi (Equidacent)]]
 
**[[Bevacizumab-maly (Alymsys)]]
 
**[[Bevacizumab-maly (Alymsys)]]
−
**[[Bevacizumab-aybi (Aybintio)]]
 
−
**[[Bevacizumab-equi (Equidacent)]]
 
 
**[[Bevacizumab-onbe (Onbevzi)]]
 
**[[Bevacizumab-onbe (Onbevzi)]]
 +
**[[Bevacizumab-tnjn (Avzivi)]] '''FDA approved 2023-12'''
 
*[[Bexarotene (Targretin)]]
 
*[[Bexarotene (Targretin)]]
 
*[[Bicalutamide (Casodex)]]
 
*[[Bicalutamide (Casodex)]]
Line 125: Line 127:
 
*[[Chlorambucil (Leukeran)]]
 
*[[Chlorambucil (Leukeran)]]
 
*[[Chlorozotocin (DCNU)]]
 
*[[Chlorozotocin (DCNU)]]
−
*[[Ciltacabtagene autoleucel (Carvykti)]] '''FDA approved 2022-03-01'''
+
*[[Ciltacabtagene autoleucel (Carvykti)]]
 
*[[Cisplatin (Platinol)]]
 
*[[Cisplatin (Platinol)]]
 
*[[Cladribine (Leustatin)]]
 
*[[Cladribine (Leustatin)]]
Line 149: Line 151:
 
*[[Daratumumab and hyaluronidase (Darzalex Faspro)]]
 
*[[Daratumumab and hyaluronidase (Darzalex Faspro)]]
 
*[[Daratumumab and vorhyaluronidase (Darzquro)]]
 
*[[Daratumumab and vorhyaluronidase (Darzquro)]]
−
*[[Darinaparsin (Darvias)]] '''PMDA approved 2022-06-20'''
+
*[[Darinaparsin (Darvias)]]
 
*[[Darolutamide (Nubeqa)]]
 
*[[Darolutamide (Nubeqa)]]
 
*[[Dasatinib (Sprycel)]]
 
*[[Dasatinib (Sprycel)]]
Line 169: Line 171:
  
 
==E==
 
==E==
 +
*[[Eflornithine (Iwilfin)]] '''FDA approved 2023-12-13'''
 
*[[Elacestrant (Orserdu)]] '''FDA approved 2023-01-27'''
 
*[[Elacestrant (Orserdu)]] '''FDA approved 2023-01-27'''
 
*[[Elotuzumab (Empliciti)]]
 
*[[Elotuzumab (Empliciti)]]
Line 205: Line 208:
 
*[[Fulvestrant (Faslodex)]]
 
*[[Fulvestrant (Faslodex)]]
 
*[[Furmonertinib (Ivesa)]]
 
*[[Furmonertinib (Ivesa)]]
−
*[[Futibatinib (Lytgobi)]] '''FDA approved 2022-09-30'''
+
*[[Futibatinib (Lytgobi)]]
  
 
==G==
 
==G==
Line 237: Line 240:
 
*[[Ifosfamide (Ifex)]]
 
*[[Ifosfamide (Ifex)]]
 
*[[Imatinib (Gleevec)]]
 
*[[Imatinib (Gleevec)]]
 +
*[[Imetelstat (Rytelo)]] '''FDA approved 2024-06-06'''
 
*[[Infigratinib (Truseltiq)]]
 
*[[Infigratinib (Truseltiq)]]
 
*[[Inotuzumab ozogamicin (Besponsa)]]
 
*[[Inotuzumab ozogamicin (Besponsa)]]
Line 270: Line 274:
 
*[[Leuprolide (Lupron)]]
 
*[[Leuprolide (Lupron)]]
 
*[[Levoleucovorin (Fusilev)]]
 
*[[Levoleucovorin (Fusilev)]]
 +
*[[Lifileuecel (Contego)]] '''FDA approved 2024-02-16'''
 
*[[Lisocabtagene maraleucel (Breyanzi)]]
 
*[[Lisocabtagene maraleucel (Breyanzi)]]
 
*[[Lobaplatin (D-19466)]]
 
*[[Lobaplatin (D-19466)]]
Line 277: Line 282:
 
*[[Lurbinectedin (Zepzelca)]]
 
*[[Lurbinectedin (Zepzelca)]]
 
*[[Lutetium Lu 177 dotatate (Lutathera)]]
 
*[[Lutetium Lu 177 dotatate (Lutathera)]]
−
*[[Lutetium Lu 177 vipivotide tetraxetan (Pluvicto)]] '''FDA approved 2022-03-23'''
+
*[[Lutetium Lu 177 vipivotide tetraxetan (Pluvicto)]]
  
 
==M==
 
==M==
Line 295: Line 300:
 
*[[Mifamurtide (Mepact)]]
 
*[[Mifamurtide (Mepact)]]
 
*[[Miriplatin (Miripla)]]
 
*[[Miriplatin (Miripla)]]
−
*[[Mirvetuximab soravtansine (Elahere)]] '''FDA approved on 2022-11-14'''
+
*[[Mirvetuximab soravtansine (Elahere)]]
 
*[[Mitomycin pyelocalyceal (Jelmyto)]]
 
*[[Mitomycin pyelocalyceal (Jelmyto)]]
 
*[[Mitomycin (Mutamycin)]]
 
*[[Mitomycin (Mutamycin)]]
Line 302: Line 307:
 
*[[Mobocertinib (Exkivity)]]
 
*[[Mobocertinib (Exkivity)]]
 
*[[Mogamulizumab (Poteligeo)]]
 
*[[Mogamulizumab (Poteligeo)]]
−
*[[Mosunetuzumab (Lunsumio)]] '''FDA approved on 2022-12-22'''
+
*[[Momelotinib (Ojjaara)]] '''FDA approved 2023-09-15'''
 +
*[[Mosunetuzumab (Lunsumio)]]
 
*[[Moxetumomab pasudotox (Lumoxiti)]]
 
*[[Moxetumomab pasudotox (Lumoxiti)]]
  
 
==N==
 
==N==
−
*[[Nadofaragene firadenovec (Adstiladrin)]] '''FDA approved 2022-12-16'''
+
*[[Nadofaragene firadenovec (Adstiladrin)]]
 
*[[Naxitamab (Danyelza)]]
 
*[[Naxitamab (Danyelza)]]
 
*[[Necitumumab (Portrazza)]]
 
*[[Necitumumab (Portrazza)]]
Line 321: Line 327:
 
*[[Nirogacestat (Ogsiveo)]] '''FDA approved 2023-11-27'''
 
*[[Nirogacestat (Ogsiveo)]] '''FDA approved 2023-11-27'''
 
*[[Nivolumab (Opdivo)]]
 
*[[Nivolumab (Opdivo)]]
−
*[[Nivolumab and relatlimab (Opdualag)]] '''FDA approved 2022-03-18'''
+
*[[Nivolumab and relatlimab (Opdualag)]]
 +
*[[Nogapendekin alfa inbakicept (Anktiva)]] '''FDA approved 2024-04-22'''
 
*[[Non-pegylated liposomal doxorubicin (Myocet)]]
 
*[[Non-pegylated liposomal doxorubicin (Myocet)]]
 
*[[Norethandrolone (Nilevar)]]
 
*[[Norethandrolone (Nilevar)]]
Line 333: Line 340:
 
*[[Ofatumumab (Arzerra)]]
 
*[[Ofatumumab (Arzerra)]]
 
*[[Olaparib (Lynparza)]]
 
*[[Olaparib (Lynparza)]]
−
*[[Olutasidenib (Rezlidhia)]] '''FDA approved 2022-12-01'''
+
*[[Olutasidenib (Rezlidhia)]]
 
*[[Olverembatinib (HQP-1351)]]
 
*[[Olverembatinib (HQP-1351)]]
 
*[[Omacetaxine (Synribo)]]
 
*[[Omacetaxine (Synribo)]]
Line 345: Line 352:
 
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]]
 
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]]
 
*[[Paclitaxel, polymeric micelle-bound (Genexol-PM)]]
 
*[[Paclitaxel, polymeric micelle-bound (Genexol-PM)]]
−
*[[Pacritinib (Vonjo)]] '''FDA approved 2022-03-01'''
+
*[[Pacritinib (Vonjo)]]
 
*[[Padeliporfin (Tookad)]]
 
*[[Padeliporfin (Tookad)]]
 
*[[Palbociclib (Ibrance)]]
 
*[[Palbociclib (Ibrance)]]
Line 433: Line 440:
  
 
==T==
 
==T==
−
*[[Tabelecleucel (Ebvallo)]] '''EMA approved 2022-12-16'''
+
*[[Tabelecleucel (Ebvallo)]]
 
*[[Tafasitamab (Monjuvi)]]
 
*[[Tafasitamab (Monjuvi)]]
 
*[[Tagraxofusp (Elzonris)]]
 
*[[Tagraxofusp (Elzonris)]]
Line 442: Line 449:
 
*[[Tamibarotene (Amnoid)]]
 
*[[Tamibarotene (Amnoid)]]
 
*[[Tamoxifen (Nolvadex)]]
 
*[[Tamoxifen (Nolvadex)]]
 +
*[[Tarlatamab (Imdelltra)]] '''FDA approved 2024-05-16'''
 
*[[Tasonermin (Beromun)]]
 
*[[Tasonermin (Beromun)]]
 
*[[Tazemetostat (Tazverik)]]
 
*[[Tazemetostat (Tazverik)]]
 
*[[Tebentafusp (Kimmtrak)]]
 
*[[Tebentafusp (Kimmtrak)]]
−
*[[Teclistamab (Tecvayli)]] '''FDA approved 2022-10-25'''
+
*[[Teclistamab (Tecvayli)]]
 
*[[Tegafur and uracil (UFT)]]
 
*[[Tegafur and uracil (UFT)]]
 
*[[Tegafur, gimeracil, oteracil (Teysuno, S-1)]]
 
*[[Tegafur, gimeracil, oteracil (Teysuno, S-1)]]
Line 464: Line 472:
 
*[[Toripalimab (Loqtorzi)]] '''FDA approved 2023-10-27'''
 
*[[Toripalimab (Loqtorzi)]] '''FDA approved 2023-10-27'''
 
*[[Tositumomab and I-131 (Bexxar)]]
 
*[[Tositumomab and I-131 (Bexxar)]]
 +
*[[Tovorafenib (Ojemda)]] '''FDA approved 2024-04-23'''
 
*[[Trabectedin (Yondelis)]]
 
*[[Trabectedin (Yondelis)]]
 
*[[Trametinib (Mekinist)]]
 
*[[Trametinib (Mekinist)]]
Line 473: Line 482:
 
**[[Trastuzumab-pkrb (Herzuma)]]
 
**[[Trastuzumab-pkrb (Herzuma)]]
 
**[[Trastuzumab-qyyp (Trazimera)]]
 
**[[Trastuzumab-qyyp (Trazimera)]]
 +
**[[Trastuzumab-strf (Hercessi)]] '''FDA approved 2024-04-29'''
 
**[[Trastuzumab-zerc (Zercepac)]]
 
**[[Trastuzumab-zerc (Zercepac)]]
 
*[[Trastuzumab and hyaluronidase (Herceptin Hylecta)]]
 
*[[Trastuzumab and hyaluronidase (Herceptin Hylecta)]]
 
*[[Trastuzumab deruxtecan (Enhertu)]]
 
*[[Trastuzumab deruxtecan (Enhertu)]]
 
*[[Trastuzumab emtansine (Kadcyla)]]
 
*[[Trastuzumab emtansine (Kadcyla)]]
−
*[[Tremelimumab (Imjudo)]] '''FDA approved 2022-10-21'''
+
*[[Tremelimumab (Imjudo)]]
 
*[[Treosulfan (Ovastat)]]
 
*[[Treosulfan (Ovastat)]]
 
*[[Trifluridine and tipiracil (Lonsurf)]]
 
*[[Trifluridine and tipiracil (Lonsurf)]]
Line 489: Line 499:
 
*[[Ublituximab (Briumvi)]] '''FDA approved 2023-01-06'''
 
*[[Ublituximab (Briumvi)]] '''FDA approved 2023-01-06'''
 
==V==
 
==V==
−
*[[Valemetostat (Ezharmia)]] '''PMDA approved 2022-09-26'''
+
*[[Valemetostat (Ezharmia)]]
 
*[[Valrubicin (Valstar)]]
 
*[[Valrubicin (Valstar)]]
 
*[[Vandetanib (Caprelsa)]]
 
*[[Vandetanib (Caprelsa)]]
Line 508: Line 518:
 
*[[Zimberelimab (Yu Duo)]]
 
*[[Zimberelimab (Yu Duo)]]
 
*[[Ziv-aflibercept (Zaltrap)]]
 
*[[Ziv-aflibercept (Zaltrap)]]
 +
**[[Aflibercept-jbvf (Yesafili)]] '''FDA approved 2024-05'''
 +
**[[Aflibercept-yszy (Opuviz)]] '''FDA approved 2024-05'''
  
 
=Discontinued antineoplastics=
 
=Discontinued antineoplastics=
Line 576: Line 588:
 
*[[Adebrelimab (SHR-1316)]]
 
*[[Adebrelimab (SHR-1316)]]
 
*[[Adenovirus-interferon-γ (TG-1042)]]
 
*[[Adenovirus-interferon-γ (TG-1042)]]
 +
*[[Afamitresgene Autoleucel (ADP-A2M4)]]
 
*[[Afuresertib (GSK-2110183)]]
 
*[[Afuresertib (GSK-2110183)]]
 
*[[Agatolimod (PF-3512676)]]
 
*[[Agatolimod (PF-3512676)]]
Line 597: Line 610:
  
 
==C==
 
==C==
 +
*[[CARv3-TEAM-E T-cells]]
 
*[[Catumaxomab (Removab)]] '''in US clinical trials'''
 
*[[Catumaxomab (Removab)]] '''in US clinical trials'''
 
*[[Cediranib (Recentin)]]
 
*[[Cediranib (Recentin)]]
Line 607: Line 621:
  
 
*[[Dalpiciclib (SHR-6390)]]
 
*[[Dalpiciclib (SHR-6390)]]
 +
*[[Danicopan (ALXN-2040)]]
 
*[[Datopotamab deruxtecan (DS-1062)]]
 
*[[Datopotamab deruxtecan (DS-1062)]]
 
*[[Denintuzumab mafodotin (SGN-CD19A)]]
 
*[[Denintuzumab mafodotin (SGN-CD19A)]]
Line 649: Line 664:
 
*[[Idasanutlin (RG-7388)]]
 
*[[Idasanutlin (RG-7388)]]
 
*[[IMA-901]]
 
*[[IMA-901]]
−
*[[Imetelstat (GRN-163L)]]
 
 
*[[Indatuximab ravtansine (BT-062)]]
 
*[[Indatuximab ravtansine (BT-062)]]
 
*[[Ipatasertib (GDC-0068)]]
 
*[[Ipatasertib (GDC-0068)]]
−
*[[Iptacopan (LNP-023)]]
 
 
*[[IPH-2101]]
 
*[[IPH-2101]]
  
Line 678: Line 691:
 
*[[MK-2206]]
 
*[[MK-2206]]
 
*[[Mocetinostat (MGCD-0103)]]
 
*[[Mocetinostat (MGCD-0103)]]
−
*[[Momelotinib (CYT-387)]]
 
 
*[[Motesanib (AMG-706)]]
 
*[[Motesanib (AMG-706)]]
  
Line 685: Line 697:
  
 
==O==
 
==O==
−
 
+
*[[Oblimersen (Genasense)]]
 
*[[Olaptesed pegol (NOX-A12)]]
 
*[[Olaptesed pegol (NOX-A12)]]
 
*[[Onartuzumab (MetMAb)]]
 
*[[Onartuzumab (MetMAb)]]
Line 733: Line 745:
  
 
*[[Tabalumab (LY-2127399)]]
 
*[[Tabalumab (LY-2127399)]]
−
*[[Tarlatamab (AMG-757)]]
 
 
*[[Tasadenoturev (DNX-2401)]]
 
*[[Tasadenoturev (DNX-2401)]]
 
*[[Telisotuzumab vedotin (ABBV-399)]]
 
*[[Telisotuzumab vedotin (ABBV-399)]]
 +
*[[Tertomotide (GV-1001)]]
 
*[[Tesetaxel (DJ-927)]]
 
*[[Tesetaxel (DJ-927)]]
 
*[[Tesevatinib (XL-647)]]
 
*[[Tesevatinib (XL-647)]]
Line 770: Line 782:
  
 
=Supportive and other medications=
 
=Supportive and other medications=
−
''This section contains supportive drugs that are either approved or investigational. Biosimilars are also indexed here, indented below their parent compound. Note that EMA approvals do not include the four-letter suffix at this time, which we have added to distinguish the generic ingredient from the parent compound.''
+
''This section contains supportive drugs that are either approved or investigational. Biosimilars are also indexed here, indented below their parent compound. Note that EMA biosimilar approvals do not include the four-letter suffix at this time, which we have added to distinguish the generic ingredient from the parent compound.''
 
==A==
 
==A==
  
Line 804: Line 816:
  
 
==B==
 
==B==
−
*[[Betibeglogene autotemcel (Zynteglo)]] '''FDA approved 2022-08-17'''
+
*[[Betibeglogene autotemcel (Zynteglo)]]
 
*[[Betrixaban (Bevyxxa)]]
 
*[[Betrixaban (Bevyxxa)]]
 
*[[Bismuth subsalicylate (Pepto-Bismol)]]
 
*[[Bismuth subsalicylate (Pepto-Bismol)]]
Line 859: Line 871:
 
*[[Edoxaban (Savaysa)]]
 
*[[Edoxaban (Savaysa)]]
 
*[[Efanesoctocog alfa (Altuviiio)]]
 
*[[Efanesoctocog alfa (Altuviiio)]]
−
*[[Eflapegrastim (Rolvedon)]] '''FDA approved on 2022-09-09'''
+
*[[Eflapegrastim (Rolvedon)]]
 
*[[Eltrombopag (Promacta)]]
 
*[[Eltrombopag (Promacta)]]
 
*[[Emicizumab (Hemlibra)]]
 
*[[Emicizumab (Hemlibra)]]
Line 910: Line 922:
 
*[[Fondaparinux (Arixtra)]]
 
*[[Fondaparinux (Arixtra)]]
 
*[[Fosaprepitant (Emend for Injection)]]
 
*[[Fosaprepitant (Emend for Injection)]]
−
*[[Fosnetupitant (Arokaris)]] '''PMDA approved 2022-03-28'''
+
*[[Fosnetupitant (Arokaris)]]
 
*[[Furosemide (Lasix)]]
 
*[[Furosemide (Lasix)]]
  
Line 928: Line 940:
 
*[[Idarucizumab (Praxbind)]]
 
*[[Idarucizumab (Praxbind)]]
 
*[[Indomethacin (Indocin)]]
 
*[[Indomethacin (Indocin)]]
 +
*[[Iptacopan (Fabhalta)]] '''FDA approved 2023-12-05'''
 
*[[Iron dextran (INFeD)]]
 
*[[Iron dextran (INFeD)]]
 
*[[Iron sucrose (Venofer)]]
 
*[[Iron sucrose (Venofer)]]
Line 957: Line 970:
 
*[[Methyltesterone (Android)]]
 
*[[Methyltesterone (Android)]]
 
*[[Metoclopramide (Reglan)]]
 
*[[Metoclopramide (Reglan)]]
−
*[[Mitapivat (Pyrukynd)]] '''FDA approved 2022-02-17'''
+
*[[Mitapivat (Pyrukynd)]]
 
*[[Motixafortide (Aphexda)]] '''FDA approved 2023-09'''
 
*[[Motixafortide (Aphexda)]] '''FDA approved 2023-09'''
 
*[[Mycophenolate mofetil (CellCept)]]
 
*[[Mycophenolate mofetil (CellCept)]]
Line 1,025: Line 1,038:
 
*[[Rolapitant (Varubi)]]
 
*[[Rolapitant (Varubi)]]
 
*[[Romiplostim (Nplate)]]
 
*[[Romiplostim (Nplate)]]
 +
*[[Rusfertide (PTG-300)]]
  
 
==S==
 
==S==
Line 1,034: Line 1,048:
 
*[[Sirolimus (Rapamune)]]
 
*[[Sirolimus (Rapamune)]]
 
*[[Sodium thiosulfate (Pedmark)]]
 
*[[Sodium thiosulfate (Pedmark)]]
−
*[[Sutimlimab (Enjaymo)]] '''FDA approved 2022-02-04'''
+
*[[Sutimlimab (Enjaymo)]]
  
 
==T==
 
==T==
Line 1,078: Line 1,092:
  
 
=By Category=
 
=By Category=
−
''Selecting a category here will take you to a new page listing all drugs in that category (note: drug categorization is still in process so not all of these links are active).''
+
''Selecting a category here will take you to a new page listing all drugs in that category (note: drug categorization is an ongoing process so not all of these links are active or current).''
  
 
==[[:Category:REMS_program|Drugs in a REMS program]]==
 
==[[:Category:REMS_program|Drugs in a REMS program]]==
Line 1,225: Line 1,239:
 
*[[:Category:Anal cancer medications|Anal cancer medications]]
 
*[[:Category:Anal cancer medications|Anal cancer medications]]
 
*[[:Category:Anaplastic large cell lymphoma medications|Anaplastic large cell lymphoma medications]]
 
*[[:Category:Anaplastic large cell lymphoma medications|Anaplastic large cell lymphoma medications]]
−
*[[:Category:Basal cell and squamous cell skin cancer medications|Basal cell and squamous cell skin cancer medications]]
 
 
*[[:Category:Bladder cancer medications|Bladder cancer medications]]
 
*[[:Category:Bladder cancer medications|Bladder cancer medications]]
 
*[[:Category:Bone cancer medications |Bone cancer medications]]
 
*[[:Category:Bone cancer medications |Bone cancer medications]]
Line 1,231: Line 1,244:
 
*[[:Category:Burkitt lymphoma medications|Burkitt lymphoma medications]]
 
*[[:Category:Burkitt lymphoma medications|Burkitt lymphoma medications]]
 
*[[:Category:Cancer of unknown primary medications |Cancer of unknown primary medications]]
 
*[[:Category:Cancer of unknown primary medications |Cancer of unknown primary medications]]
−
*[[:Category:Castleman’s disease medications|Castleman’s disease medications]]
+
*[[:Category:Castleman disease medications|Castleman disease medications]]
 
*[[:Category:Central nervous system (CNS) cancer medications|Central nervous system (CNS) cancer medications]]
 
*[[:Category:Central nervous system (CNS) cancer medications|Central nervous system (CNS) cancer medications]]
 
*[[:Category:CNS lymphoma medications|Central nervous system (CNS) lymphoma medications]]
 
*[[:Category:CNS lymphoma medications|Central nervous system (CNS) lymphoma medications]]
Line 1,240: Line 1,253:
 
*[[:Category:Colon cancer medications|Colon cancer medications]]
 
*[[:Category:Colon cancer medications|Colon cancer medications]]
 
*[[:Category:Colorectal cancer medications|Colorectal cancer (CRC) medications]]
 
*[[:Category:Colorectal cancer medications|Colorectal cancer (CRC) medications]]
 +
*[[:Category:Cutaneous basal cell carcinoma medications|Cutaneous BCC medications]]
 +
*[[:Category:Cutaneous squamous cell carcinoma medications|Cutaneous SCC medications]]
 
*[[:Category:Cutaneous T-cell lymphoma medications|Cutaneous T-cell lymphoma medications]]
 
*[[:Category:Cutaneous T-cell lymphoma medications|Cutaneous T-cell lymphoma medications]]
 
*[[:Category:Diffuse large B-cell lymphoma medications|Diffuse large B-cell lymphoma medications]]
 
*[[:Category:Diffuse large B-cell lymphoma medications|Diffuse large B-cell lymphoma medications]]
Line 1,302: Line 1,317:
 
*[[:Category:Subcutaneous medications|Subcutaneous (SC) medications]]
 
*[[:Category:Subcutaneous medications|Subcutaneous (SC) medications]]
  
−
==Medications by Year of Approval==
+
==Medications by FDA Year of Approval==
  
 
<div style="column-count:3;-moz-column-count:3;-webkit-column-count:3">
 
<div style="column-count:3;-moz-column-count:3;-webkit-column-count:3">
Line 1,379: Line 1,394:
 
*[[:Category:FDA approved in 2022|FDA approved in 2022]]
 
*[[:Category:FDA approved in 2022|FDA approved in 2022]]
 
*[[:Category:FDA approved in 2023|FDA approved in 2023]]
 
*[[:Category:FDA approved in 2023|FDA approved in 2023]]
 +
*[[:Category:FDA approved in 2024|FDA approved in 2024]]
 
</div>
 
</div>
  

Revision as of 17:57, 9 June 2024

Back to Top

Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

Other interesting and helpful links can be found by clicking the link.

Chemotherapy safety standards

Dose adjustments

Antimicrobials

Growth factors

Approved antineoplastics

This section contains anticancer drugs that have had at least one formal approval in any domain (FDA, EMA, etc). Biosimilars are also indexed here, indented below their parent compound. Note that EMA biosimilar approvals do not include the four-letter suffix at this time, which we have added to distinguish the generic ingredient from the parent compound. For drugs first approved within the current or prior calendar years, the date of initial approval is also provided here.

A

B

C

D

E

F

G

H

I

K

L

M

N

O

P

Q

R

S

T

U

V

Z

Discontinued antineoplastics

This section contains drugs that have had at least one formal approval in any domain (FDA, EMA, etc), but are no longer on the market. Note that it is possible that these drugs continue to be available in some limited way, such as through compassionate use programs.

A

D

E

F

L

M

O

P

S

T

U

V

Investigational antineoplastics

This list is far from exhaustive. Drugs are included here generally once there are some encouraging preliminary results. Since is it very difficult to tell when a company has stopped development on a drug, this list may also include drugs that are no longer under investigation.

A

B

C

D

E

F

G

H

I

J

L

M

N

O

P

Q

R

S

T

U

V

Z

Supportive and other medications

This section contains supportive drugs that are either approved or investigational. Biosimilars are also indexed here, indented below their parent compound. Note that EMA biosimilar approvals do not include the four-letter suffix at this time, which we have added to distinguish the generic ingredient from the parent compound.

A

B

C

D

E

F

G

H

I

L

M

N

O

P

Q

R

S

T

U

V

W

Z

By Category

Selecting a category here will take you to a new page listing all drugs in that category (note: drug categorization is an ongoing process so not all of these links are active or current).

Drugs in a REMS program

Cytotoxic Chemotherapy

Kinase inhibitors

Endocrine therapy

Investigational and Discontinued

Biologics

Supportive Medications

Radioactive agents

Benign Hematology Medications

Hematopoietic Growth Factors

Miscellaneous

Medications by Condition

Medications by Route of Administration

Medications by FDA Year of Approval

Interesting and Helpful Links

References

  1. ↑ Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH. Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2012 May 1;30(13):1553-61. Epub 2012 Apr 2. link to original article PubMed
  2. ↑ Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015 Oct 1;33(28):3199-212. Epub 2015 Jul 13. link to original article PubMed
  3. ↑ Mancini R, Modlin J. Chemotherapy Administration Sequence: A Review of the Literature and Creation of a Sequencing Chart. J Hematol Oncol Pharm. 2011;1(1):17-25. link to original article
Retrieved from "https://hemonc.org/w/index.php?title=Drug_index&oldid=86173"